The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.

Autor:	Martín-García D; Surgical Specialties, Biochemistry and Immunology, University of Malaga, Spain., Téllez T; Surgical Specialties, Biochemistry and Immunology, University of Malaga, Spain., Redondo M; Surgical Specialties, Biochemistry and Immunology, University of Malaga, Spain., García-Aranda M; Surgical Specialties, Biochemistry and Immunology, University of Malaga, Spain.; Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain.
Jazyk:	angličtina
Zdroj:	Current medicinal chemistry [Curr Med Chem] 2024; Vol. 31 (39), pp. 6487-6509.
DOI:	10.2174/0109298673261625230924114406
Abstrakt:	Different studies have highlighted the role of Substance P / Neurokinin 1 Receptor (SP/NK-1R) axis in multiple hallmarks of cancer including cell transformation, proliferation, and migration as well as angiogenesis and metastasis of a wide range of solid tumors including colorectal cancer. Until now, the selective high-affinity antagonist of human SP/NK1-R aprepitant (Emend) has been authorized by the Food and Drug Administration as a low dosage medication to manage and treat chemotherapy-induced nausea. However, increasing evidence in recent years support the potential utility of high doses of aprepitant as an antitumor agent and thus, opening the possibility to the pharmacological repositioning of SP/NK1-R antagonists as an adjuvant therapy to conventional cancer treatments. In this review, we summarize current knowledge on the molecular basis of colorectal cancer as well as the pathophysiological importance of SP/NK1-R and the potential utility of SP/NK-1R axis as a therapeutic target in this malignancy. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu